Skip to main content

Vertex Pharmaceuticals statistics

  • VRTX · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$538.60−0.74%Close 13 Nov 2026

Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.

Valuation

Enterprise value$136.7B
EV / EBITDA30.11
EV / sales10.56

Share price

Latest close$538.60
Day's change−0.7%
52-week high$568.67
52-week low$412.27
From 52-week high−5.3%
Return · 1 month+7.8%
Return · 3 months−0.3%
Return · year to date+18.8%
Return · 1 year+24.0%
Beta · 1 year against the S&P 5000.43
50-day average$522.37
200-day average$483.34
RSI 1452.8
Average volume · 20 sessions1.5M

Margins and returns

For fiscal 2025, as filed.

Gross margin86.2%
Operating margin34.8%
Net margin32.9%
Free cash flow margin26.6%
Return on equity22.5%
Return on assets14.8%
Return on invested capital25.1%
Return on capital employed20.5%
Stock-based compensation / revenue5.7%

Financial position

At the end of fiscal 2025.

Cash and equivalents$5.08B
Total debt$1.92B
Net debt−$4.68B
Current ratio2.90
Debt / equity0.10
Net debt / EBITDA−1.07
Interest coverage313.78

Shares and dividends

For fiscal 2025, as filed.

Diluted shares258M
Net share repurchases$1.96B

Taxes

For fiscal 2025, as filed.

Income tax expense$690.0M
Effective tax rate14.9%

VRTX in the terminal

Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.